Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

VMAT2-Deficient Mice Display Nigral and Extranigral Pathology and Motor and Nonmotor Symptoms of Parkinson's Disease.

Taylor TN, Caudle WM, Miller GW.

Parkinsons Dis. 2011 Feb 21;2011:124165. doi: 10.4061/2011/124165.

2.

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity.

Taylor TN, Caudle WM, Shepherd KR, Noorian A, Jackson CR, Iuvone PM, Weinshenker D, Greene JG, Miller GW.

J Neurosci. 2009 Jun 24;29(25):8103-13. doi: 10.1523/JNEUROSCI.1495-09.2009.

3.

Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus.

Taylor TN, Alter SP, Wang M, Goldstein DS, Miller GW.

Neuropharmacology. 2014 Jan;76 Pt A:97-105. doi: 10.1016/j.neuropharm.2013.08.033. Epub 2013 Sep 8.

4.
5.

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration.

Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, Miller GW.

J Neurosci. 2007 Jul 25;27(30):8138-48.

6.

Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease.

Miller GW, Wang YM, Gainetdinov RR, Caron MG.

Methods Mol Med. 2001;62:179-90. doi: 10.1385/1-59259-142-6:179.

PMID:
21318776
7.
8.

Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice.

Sathiya S, Ranju V, Kalaivani P, Priya RJ, Sumathy H, Sunil AG, Babu CS.

Neuropharmacology. 2013 Oct;73:98-110. doi: 10.1016/j.neuropharm.2013.05.025. Epub 2013 Jun 6.

PMID:
23747572
9.

Vesicular monoamine transporter 2 regulates the sensitivity of rat dopaminergic neurons to disturbed cytosolic dopamine levels.

Vergo S, Johansen JL, Leist M, Lotharius J.

Brain Res. 2007 Dec 14;1185:18-32. Epub 2007 Sep 21.

PMID:
18028884
10.

Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.

Alter SP, Stout KA, Lohr KM, Taylor TN, Shepherd KR, Wang M, Guillot TS, Miller GW.

Exp Neurol. 2016 Jan;275 Pt 1:17-24. doi: 10.1016/j.expneurol.2015.09.016. Epub 2015 Sep 30.

11.

Increased vesicular monoamine transporter enhances dopamine release and opposes Parkinson disease-related neurodegeneration in vivo.

Lohr KM, Bernstein AI, Stout KA, Dunn AR, Lazo CR, Alter SP, Wang M, Li Y, Fan X, Hess EJ, Yi H, Vecchio LM, Goldstein DS, Guillot TS, Salahpour A, Miller GW.

Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977-82. doi: 10.1073/pnas.1402134111. Epub 2014 Jun 16.

12.

VMAT2 and Parkinson's disease: harnessing the dopamine vesicle.

Lohr KM, Miller GW.

Expert Rev Neurother. 2014 Oct;14(10):1115-7. doi: 10.1586/14737175.2014.960399. Epub 2014 Sep 14.

13.

Differential gene expression in the striatum of mice with very low expression of the vesicular monoamine transporter type 2 gene.

Colebrooke RE, Chan PM, Lynch PJ, Mooslehner K, Emson PC.

Brain Res. 2007 Jun 4;1152:10-6. Epub 2007 Mar 15.

PMID:
17433807
14.

VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease.

Chen MK, Kuwabara H, Zhou Y, Adams RJ, Brasić JR, McGlothan JL, Verina T, Burton NC, Alexander M, Kumar A, Wong DF, Guilarte TR.

J Neurochem. 2008 Apr;105(1):78-90. Epub 2007 Nov 5.

15.

A fluorescent-based assay for live cell, spatially resolved assessment of vesicular monoamine transporter 2-mediated neurotransmitter transport.

Bernstein AI, Stout KA, Miller GW.

J Neurosci Methods. 2012 Aug 15;209(2):357-66. doi: 10.1016/j.jneumeth.2012.06.002. Epub 2012 Jun 12.

17.

Positive immunoreactivity for vesicular monoamine transporter 2 in Lewy bodies and Lewy neurites in substantia nigra.

Yamamoto S, Fukae J, Mori H, Mizuno Y, Hattori N.

Neurosci Lett. 2006 Apr 3;396(3):187-91. Epub 2005 Dec 28.

PMID:
16386370
19.

Inverse relationship between the contents of neuromelanin pigment and the vesicular monoamine transporter-2: human midbrain dopamine neurons.

Liang CL, Nelson O, Yazdani U, Pasbakhsh P, German DC.

J Comp Neurol. 2004 May 17;473(1):97-106.

PMID:
15067721
20.

Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease.

Harrington KA, Augood SJ, Kingsbury AE, Foster OJ, Emson PC.

Brain Res Mol Brain Res. 1996 Feb;36(1):157-62.

PMID:
9011752
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk